

CASTRATION-RESISTANT PROSTATE CANCER: 4 YEARS OF EXPERIENCE

Villacañas Palomares MV, Sáez Fernández EM, Martín García G, Fernández Domínguez E,
Calvo Hernández MV

Complejo Asistencial Universitario de Salamanca

DI-034

OBJECTIVE

To analyse the compliance with authorised use criteria, the response to, and safety of abiraterone in clinical practice in a tertiary hospital

MATERIALS AND METHODS

- Retrospective observational study
- January 2011-December 2014

Variables collected:

- ✓ Age
- ✓ Performance status
- ✓ Stage of the disease
- ✓ Location and existence metastases
- ✓ Pre-treatments, treatment, duration, causes of interruption
- ✓ Prostatic specific antigen (PSA)
- ✓ Tolerance and safety


Use criteria:

- ✓ Performance status: ECOG ≤ 2 and Gleason < 8
- ✓ Serum transaminase levels < 2.5 upper limit normal
- ✓ Presence of bone or/and node but no visceral metastases


RESULTS

- 54 patients
- Median age: 76 years old (57-85)
- Patients in treatment at the end of the study: 16 patients
- Treatments finished: 38 patients
- Median time for finished treatments: 6,1 months (1-31)
- Causes of discontinuation: 79% lack of efficacy, 5% death, 8% adverse events or intolerance and 8% another cause

TOLERANCE



CONSISTENT WITH USE CRITERIA



CONCLUSIONS

Efficacy and safety results were similar to other studies, the outputs of a pharmacoeconomic analysis could help in the decision making process.

Most patients with the required information available were consistent with the use criteria.

The absent data from the clinical history shows that new tools to register and consult clinical data are needed.